-       Report 
   - October 2024
    -  203 Pages 
    Global
   
   From       €5716EUR$6,360USD£5,013GBP 
      €7146EUR$7,950USD£6,267GBP 
                  -       Drug Pipelines 
   - August 2024
    -  150 Pages 
    Global
   
   From       €2696EUR$3,000USD£2,365GBP 
      €3371EUR$3,750USD£2,956GBP 
                  -       Report 
   - August 2024
    -  121 Pages 
    Global
   
   From       €5716EUR$6,360USD£5,013GBP 
      €7146EUR$7,950USD£6,267GBP 
                  -       Drug Pipelines 
   - July 2024
    -  150 Pages 
    Global
   
   From       €2696EUR$3,000USD£2,365GBP 
      €3371EUR$3,750USD£2,956GBP 
                  -       Report 
   - July 2024
    -  100 Pages 
    Global
   
   From       €2696EUR$3,000USD£2,365GBP 
      €3371EUR$3,750USD£2,956GBP 
                   -       Report 
   - July 2024
    -  100 Pages 
    Global
   
   From       €2696EUR$3,000USD£2,365GBP 
      €3371EUR$3,750USD£2,956GBP 
                  -       Report 
   - January 2024
    -  125 Pages 
    Global
   
   From       €5716EUR$6,360USD£5,013GBP 
      €7146EUR$7,950USD£6,267GBP 
                  -       Report 
   - February 2023
    -  164 Pages 
    Global
   
   From       €5393EUR$6,000USD£4,730GBP 
      €6741EUR$7,500USD£5,912GBP 
                -       Report 
   - April 2023
    -  115 Pages 
    Global
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - April 2023
    -  115 Pages 
    Global
   
   From       €4269EUR$4,750USD£3,744GBP 
                  -       Report 
   - May 2024
    -  130 Pages 
    Global
   
   From       €4965EUR$5,524USD£4,354GBP 
      €5841EUR$6,499USD£5,123GBP 
                  -       Report 
   - May 2024
    -  130 Pages 
    Global
   
   From       €4965EUR$5,524USD£4,354GBP 
      €5841EUR$6,499USD£5,123GBP 
                  -       Report 
   - May 2024
    -  133 Pages 
    Global
   
   From       €4965EUR$5,524USD£4,354GBP 
      €5841EUR$6,499USD£5,123GBP 
                  -       Report 
   - May 2024
    -  137 Pages 
    Global
   
   From       €4965EUR$5,524USD£4,354GBP 
      €5841EUR$6,499USD£5,123GBP 
                  -       Report 
   - May 2024
    -  134 Pages 
    Global
   
   From       €4965EUR$5,524USD£4,354GBP 
      €5841EUR$6,499USD£5,123GBP 
                  -       Report 
   - May 2024
    -  138 Pages 
    Global
   
   From       €4965EUR$5,524USD£4,354GBP 
      €5841EUR$6,499USD£5,123GBP 
                  -       Report 
   - May 2024
    -  134 Pages 
    Global
   
   From       €4965EUR$5,524USD£4,354GBP 
      €5841EUR$6,499USD£5,123GBP 
                  -       Report 
   - May 2024
    -  128 Pages 
    Global
   
   From       €4965EUR$5,524USD£4,354GBP 
      €5841EUR$6,499USD£5,123GBP 
                  -       Report 
   - May 2024
    -  132 Pages 
    Global
   
   From       €4965EUR$5,524USD£4,354GBP 
      €5841EUR$6,499USD£5,123GBP 
                  -       Report 
   - May 2024
    -  131 Pages 
    Global
   
   From       €4965EUR$5,524USD£4,354GBP 
      €5841EUR$6,499USD£5,123GBP 
             
         The Bronchodilator market is composed of inhalers and nebulisers, both of which are used to treat respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD). Inhalers are handheld devices that deliver medication directly to the lungs in the form of a mist or spray. Nebulisers are larger machines that convert liquid medication into a fine mist that can be inhaled. Both inhalers and nebulisers are used to deliver bronchodilators, which are medications that relax the muscles    in the airways and make it easier to breathe.
Inhalers are the most commonly used form of bronchodilator delivery, as they are more convenient and cost-effective than nebulisers. Inhalers come in a variety of forms, including metered dose inhalers (MDIs), dry powder inhalers (DPIs), and soft mist inhalers (SMIs). Nebulisers are typically used for more severe cases of respiratory conditions, as they can deliver a higher dose of medication than inhalers.
Some of the companies in the Bronchodilator market include GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, and Merck. Show Less   Read more